Enzyme Inhibition in the Lab
Competitive And Noncompetitive Inhibition
You're running an enzyme kinetics experiment and the velocity just isn't what the textbook says it should be. More often than not, you've got an inhibitor in the mix. The first step is figuring out what kind you're dealing with, because the math and the follow-up are completely different for each. I spent way too many years watching grad students confuse the two and then waste weeks trying to force the wrong Lineweaver-Burk plot to line up. It's not glamorous. Let me save you that trouble. Competitive inhibition happens when the inhibitor looks enough like the substrate to sit in the active site. It doesn't break anything. It just occupies the spot where the real substrate wants to bind, so the enzyme can't do its job at that moment. Add more substrate and you push the inhibitor out. The Vmax stays the same. That's the defining feature. The Km increases because you need more substrate to reach half-maximal velocity.
Noncompetitive inhibition is different. The inhibitor binds somewhere else entirely. It can attach whether the substrate is already bound or not. Binding at this allosteric site changes the enzyme's shape enough that catalysis slows down even when substrate is sitting right in the active site. Adding more substrate does nothing. The Vmax drops. The Km usually stays the same, which tells you substrate affinity hasn't changed. The enzyme is just less efficient. Here's how I actually determine which is which in practice. You run the assay at several substrate concentrations with and without the inhibitor. Then you plot a Lineweaver-Burk graph. If the lines intersect on the y-axis, you're looking at competitive inhibition. Same Vmax, different slopes. If the lines intersect on the x-axis, that's noncompetitive. Same Km, different y-intercepts. If they cross somewhere in between, you're dealing with mixed inhibition, which is neither purely competitive nor purely noncompetitive. I had a problem last year with a kinase assay where the inhibitor seemed to be competitive at low micromolar concentrations but shifted to noncompetitive behavior as I increased the concentration. Turned out the compound was aggregating at higher concentrations, which is a classic artifact. The aggregate form binds off-site and mimics noncompetitive inhibition. I confirmed it by running a DLS measurement before and after each assay, and sure enough, the aggregation started around 50 µM. I diluted the inhibitor below that threshold and re-ran everything. The data went back to clean competitive behavior.
One thing people consistently miss is that Ki values aren't interchangeable between inhibition types. A Ki from a competitive assay tells you about binding affinity at the active site. A Ki from a noncompetitive assay tells you about affinity at an allosteric site. They're measuring different things. Don't compare them directly or pretend they mean the same thing. Another thing that trips people up: pure noncompetitive inhibition is actually rare in real biological systems. Most allosteric inhibitors show some mixed character. You'll see Km shift slightly even when the mechanism is primarily noncompetitive. The textbook diagrams make it look cleaner than it is. If your data shows a small Km change alongside a clear Vmax drop, don't throw the data out. It's still useful. Just call it mixed noncompetitive instead of forcing it into the pure category. For competitive inhibitors, the key practical takeaway is that you can overcome the inhibition by increasing substrate concentration. This matters a lot in drug design. If you're developing a drug that acts as a competitive inhibitor, you need to make sure the target tissue has enough substrate that the drug can still compete effectively. If the natural substrate concentration is already near saturation, the drug won't add much inhibition on top of that.
For noncompetitive inhibitors, there's no workaround through substrate concentration. That's also what makes them attractive as drugs in some cases. They work regardless of how much substrate is present. The downside is that off-target effects become more likely because the allosteric site may not be as evolutionarily conserved or specific as the active site. When you're reading papers about these inhibitors, check whether they reported IC50 values or Ki values. IC50 depends on substrate concentration for competitive inhibitors but not for pure noncompetitive ones. So an IC50 you read in one paper might not be comparable to an IC50 in another paper if the substrate concentrations differed. Always convert to Ki if you're comparing across studies. The Cheng-Prusoff equation handles the competitive case. I keep a quick reference sheet in my lab notebook with the Michaelis-Menten equations modified for each inhibition type. It saves time when I'm fitting data because I don't have to re-derive them every time. For competitive inhibition, V equals Vmax times S divided by Km times one plus I over Ki plus S. For noncompetitive, the equation changes to include the alpha prime term because the inhibitor affects catalysis as well as binding.
If you're new to this, start with the competitive case. The data is easier to interpret and the plots are cleaner. Once you've done a few competitive inhibition experiments and can spot the pattern by eye, move on to noncompetitive. The mixed cases will come later. Don't try to tackle everything at once.
